#1 Clinical Trials Search in Europe

Bt8009

BT8009 is an innovative drug currently being studied in clinical trials for the treatment of various advanced solid tumors, particularly focusing on urothelial cancer and other Nectin-4 expressing malignancies. These trials aim to evaluate the safety, efficacy, and optimal dosing of BT8009 both as a monotherapy and in combination with other drugs like pembrolizumab. The studies involve patients with different types of cancer, including bladder cancer, breast cancer, and lung cancer, among others.

Table of Contents

What is BT8009?

BT8009, also known as zelenectide pevedotin, is a new type of cancer drug called a Bicyclic Toxin Conjugate (BTC)[1]. It is currently being studied as a potential treatment for various types of advanced solid tumors, particularly those that express a protein called Nectin-4[1]. This innovative medication is designed to target cancer cells more precisely than traditional chemotherapy, potentially offering better effectiveness with fewer side effects.

How BT8009 Works

BT8009 works by combining two important components:

  1. A targeting molecule that seeks out cancer cells expressing Nectin-4
  2. A toxic substance called monomethyl auristatin E (MMAE) that kills cancer cells

This combination allows BT8009 to deliver the toxic MMAE directly to cancer cells while minimizing damage to healthy cells[1]. The drug circulates in the bloodstream, attaches to cancer cells expressing Nectin-4, and then releases the MMAE inside the cancer cells to destroy them.

Conditions Treated by BT8009

BT8009 is being studied for the treatment of several types of advanced solid tumors, including[1]:

  • Urinary Bladder Cancer: Cancer that starts in the bladder
  • Triple Negative Breast Cancer: An aggressive type of breast cancer that lacks certain receptors
  • Hormone Receptor Positive Breast Cancer: Breast cancers that are sensitive to hormones
  • Non-Small-Cell Lung Cancer: The most common type of lung cancer
  • Ovarian Cancer: Cancer that begins in the ovaries
  • Other Advanced Solid Tumors: Various types of cancers that have spread or cannot be surgically removed

BT8009 is particularly promising for metastatic urothelial cancer, which is an advanced form of bladder cancer that has spread to other parts of the body[2].

Clinical Trials Involving BT8009

BT8009 is currently being studied in several clinical trials to determine its safety and effectiveness. Two major studies are:

  1. Study BT8009-100: This is a Phase I/II study examining BT8009 alone and in combination with another drug called pembrolizumab in patients with advanced solid tumors[1].
  2. Duravelo-2 Study (BT8009-230): This is a larger Phase 2/3 study focusing specifically on patients with locally advanced or metastatic urothelial cancer[2].

These trials are designed to determine the best dose of BT8009, how well it works against different types of cancer, and what side effects it might cause.

How BT8009 is Administered

BT8009 is given to patients through an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein. The dosing schedule can vary depending on the specific trial and treatment plan, but some common schedules include[1][2]:

  • Weekly: Given on days 1, 8, 15, and 22 of a 28-day cycle
  • Biweekly: Given on days 1 and 15 of a 28-day cycle
  • Every 3 weeks: Given on days 1 and 8 of a 21-day cycle

The exact schedule and dose may be adjusted based on how well a patient tolerates the treatment and how their cancer responds.

BT8009 in Combination Therapy

In some clinical trials, BT8009 is being studied in combination with other cancer treatments, particularly a drug called pembrolizumab (also known as Keytruda)[1][2]. Pembrolizumab is an immunotherapy drug that helps the body’s immune system recognize and fight cancer cells. The combination of BT8009 and pembrolizumab may provide enhanced anti-cancer effects compared to either treatment alone.

Safety and Side Effects

As with all cancer treatments, BT8009 may cause side effects. The clinical trials are carefully monitoring patients for any adverse reactions. Common side effects of cancer treatments can include fatigue, nausea, and decreased blood cell counts. However, the specific side effects of BT8009 are still being determined through the ongoing clinical trials[1][2].

Researchers are also studying how BT8009 affects patients with kidney problems (renal insufficiency) to ensure it can be used safely in these individuals[1].

Future Prospects for BT8009

The ongoing clinical trials will help determine the full potential of BT8009 in treating various types of cancer. If the results are positive, BT8009 could become an important new option for patients with advanced solid tumors, particularly those with metastatic urothelial cancer[2].

Researchers are not only studying how well BT8009 works to shrink tumors and prolong survival, but also how it affects patients’ quality of life. This comprehensive approach aims to ensure that BT8009 can provide meaningful benefits to patients beyond just treating their cancer[2].

Aspect Details
Drug Name BT8009 (zelenectide pevedotin)
Type of Drug Bicyclic Toxin Conjugate (BTC)
Target Nectin-4 expressing advanced malignancies
Main Cancer Types Urothelial cancer, breast cancer, non-small-cell lung cancer, ovarian cancer
Administration Intravenous (IV) infusion
Trial Phases Phase 1/2 and Phase 2/3
Treatment Approaches Monotherapy and combination with pembrolizumab
Primary Outcomes Safety, tolerability, objective response rate, pharmacokinetics
Secondary Outcomes Duration of response, progression-free survival, overall survival

FAQ

  • What is BT8009? BT8009 is a Bicyclic Toxin Conjugate (BTC) drug being investigated for the treatment of advanced solid tumors, particularly those expressing Nectin-4. It's designed to target cancer cells more specifically than traditional chemotherapy.
  • What types of cancer is BT8009 being tested for? BT8009 is being tested for various advanced solid tumors, including urothelial (bladder) cancer, breast cancer (including triple-negative and hormone receptor-positive types), non-small-cell lung cancer, ovarian cancer, and other Nectin-4 expressing malignancies.
  • How is BT8009 administered to patients? BT8009 is administered intravenously (IV) on different schedules depending on the study arm. It may be given weekly, biweekly, or on specific days of a 21-day or 28-day cycle.
  • Is BT8009 being tested alone or with other drugs? BT8009 is being tested both as a monotherapy (alone) and in combination with other drugs, particularly pembrolizumab, which is an immunotherapy drug.
  • What are the main goals of the BT8009 clinical trials? The main goals of the BT8009 clinical trials are to assess its safety and tolerability, determine the optimal dose, evaluate its effectiveness in shrinking tumors (measured by objective response rate), and study how long the drug stays in the body (pharmacokinetics).

Ongoing Clinical Trials on Bt8009

  • Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

    Not yet recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Nectin-4: A protein found on the surface of certain cancer cells, which BT8009 is designed to target.
  • Urothelial Cancer: A type of cancer that typically occurs in the urinary system, most commonly in the bladder.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Monotherapy: Treatment using a single drug.
  • Pembrolizumab: An immunotherapy drug that helps the immune system fight cancer cells.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Dose-limiting toxicity: Side effects of a drug that are severe enough to prevent increasing the dose.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.

References